Latest News and Press Releases

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily...

Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right...

Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in...

SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that...

SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...

Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase ...

In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting...

SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that...

SCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that...

National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09,...